Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo

The use of irinotecan to treat metastatic colorectal cancer (CRC) is limited by unpredictable response and variable toxicity; however, no reliable clinical biomarkers are available. Here, we report a study to ascertain whether irinotecan-induced DNA damage measures are suitable/superior biomarkers o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wood, Joanna P, Smith, Andrew J O, Bowman, Karen J, Thomas, Anne L, Jones, George D D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567016/
https://www.ncbi.nlm.nih.gov/pubmed/26108357
http://dx.doi.org/10.1002/cam4.477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567016/
https://www.ncbi.nlm.nih.gov/pubmed/26108357
http://dx.doi.org/10.1002/cam4.477

Ejemplares similares